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1. Introduction
  MiR-155 is widely expressed in various cells, such as T cells, B 
cells, mononuclear cells and endothelial cells. As a multifunction 
miRNA, it is extensively involved with the differentiation, 
proliferation and apoptosis of many cells, and the development 
of many tissues[1]. MiR-155 can inhibit inflammatory response 
and affect lipid uptake in macrophages through regulating other 
targets[2,3]. CAD is a kind of inflammatory disease closely related to 
lipid metabolism. There are no obvious symptoms during the early 
stage of CAD. However, as stable plaque develops into a vulnerable 
plaque, the fibrous cap may rupture and expose the liquid in the 
plaque, which could activate the fibrinolytic system in circulation. 
Eventually, occlusive thrombus may form, causing myocardial 
infarction[4-6]. Stephan Fichtlscherer et al[7] measured the miR-
155 levels of patients with CAD and healthy patients; the results 
showed that miR-155 levels clearly declined for patients with CAD, 
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apoptosis effort of OxLDL to RAW264.7 macrophagocyte.
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compared with healthy patients. Huang et al[8] found a marked 
increase in the protein amount of the myeloid differentiation primary 
response gene 88 (MyD88), which can activate the NF-毷B pathway. 
The results demonstrated that miR-155 serves as a negative feedback 
regulator in oxLDL-stimulated THP-1 inflammatory responses and 
lipid uptake. These phenomena suggest that miR-155 may be closely 
related to the disease. However, the relationship of miR-155 with the 
severity of the disease and the action mechanism is still unclear.
  To investigate the clinical value of miR-155 in the diagnosis of 
CAD, we detected the miR-155 expression levels in plasma and 
mononuclear cells of peripheral blood from patients with different 
severities of CAD, analyzed the effort of miR-155 on the apoptosis 
of macrophage; the correlation of miR-155 with the severity of 
CAD. 
2. Materials and methods
2.1. Materials
  miR-155 mimics and miR-155 inhibitor were purchased from the 
Gene Pharma; OxLDL was purchased from the Beijing Xiesheng 
biological technology; DMEM culture medium and fetal calf serum 
were provided by HyClone; trypsin and MTT were from Sigma; 
total RNA isolation kit and Fist Strand cDNA Synthesis kit were 
from TaKaRa Bio Inc. Real-time PCR was purchased from Thermo; 
microplate reader was from Molecular Devices.
2.2. Cell isolation 
  The blood sample was provided by Shanghai East hospital. There 
were four kind of blood samples, namely blood form patients 
with acute myocardial infarction (AMI group), patients with 
tunstable angina pectoris (UAP group), patients with stable angina 
pectoris (SAP group), and patients with chest pain syndrome (CPS 
group). PBMCs were isolated from the blood by density gradient 
centrifugation method using lymphocyte isolation liquid. After 
centrifugation, the liquid divided into 3 layers; cells on the top of 
the forth layer were collected into a centrifuge tube, and was re-
suspended by PBS. The liquid was centrifuged in 1 500 rpm for 
15 minutes, then the supernatant was abandoned. The process was 
repeated for three times. 
2.3. Transfect macrophage with miR-155 OligoRNA
  RAW 264.7 was seeded in the 24 plate (2伊105/well), and cultured 
to 80% confluence for later use. Lipofectamin 2000 (1 毺L/well) 
and FAM-siRNA (2 毺L/well) were diluted by 50 毺L Opti-MEMI 
Reduced Serum Medium respectively, and cultured for 5 min; Mix 
the solution thoroughly and let it stand for about 20 min before using 
it. The FAM-siRNA-transfection reagent was added into the plate 
with culture medium, and after cultured in an incubator at 37 曟 for 
another 6 h, the liquid was replaced with DMEM culture medium 
containing 10% FBS. The cell was then collected and the expression 
level of miR-155 was analyzed by quantitative real time PCR. 
2.4. Quantitative real-time PCR analysis
  Certain amount of cell was re-suspended by PSB in a centrifuge 
tube, and an appropriate amount of Trizol was added into the 
centrifuge tube with the PBMCs. After incubating for 15 h the tube 
was centrifuged at 12 000  rpm at 4 曟 for 5 min, and the supernatant 
was removed. Total mRNA was isolated using an Eastep Universal 
RNA Extraction Kit (Promega). The RNA sample were treated 
with DNase 栺(Sigma), then quantified and reverse-transcribed 
into cDNA using a Fist Strand cDNA Synthesis kit (TAKARA). 
Quantitative real-time PCR was conducted using a RealPlex4 real-
time PCR detection system (Eppendrof) with SYBR Green Real 
time PCR Master MIS (TOYOBO). The reaction system: SYBR 
Premix Ex Taq (2伊)12.5 毺L, PCR Forward Primer (10 毺M) 1 毺L, 
PCR Reverse Primer (10 毺M) 1 毺L, DNA template 2 毺L, dH2O 
8.5 毺L. Reaction parameters: pre denaturation at 94 曟 for 30 s, 
denaturation at 95 曟 for 15 s, anneal at 60 曟 for 20 s, and extend 
at 72 曟 for 10 s. The application was performed for 40 cycles. A 
comparative threshold cycle (Ct) was used to determine the relative 
gene expression normalized to 18S rRNA for each sample, and 
the relative expression level of each sample was calculated using 
the formula, 2-△△Ct. All primers used in our study were designed 
according to the sequence published online (GenBank), and 
synthesized by Invitrogen.
2.5. MTT detect the viability of the cell
  The RAW264.7 macrophage and miR-155 overexpressed 
RAW264.7 macrophage were digested by trypsin after they achieved 
80% confluence. Adjust the concentration of the cell suspension to 2
伊105/mL, and 200 毺L/well was added into the 96 well plate. After 
cultured for 24 h, OxLDL was added to one group of the cell with 
the final concentration of 0, 20, 40, 80, 160 毺g/mL. the cell was 
cultured in an incubator at 37 曟 for another 4 h, and then the culture 
medium with MTT was abandoned, 150 毺L dimethyl sulfoxide 
(DMSO) was added to the plate to dissolve the formazan crystals 
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for 30 min. Then the absorbance was measured at 490nm using a 
Microplate reader. Corrected absorbance values were obtained by 
subtracting the blank absorbance from the absorbance obtained. 
OxLDL was added to the other group with the final concentration 
of 80 毺g/mL, after cultured for 1, 3, 6, 12, 24, 48 h, detect the 
absorbance as we described above.
2.6. Statistical analysis
  In this study, SPSS 13.0 software was used for statistical analysis. 
The measured data were expressed as mean依SD, and t-test was 
applied to the results for statistical analysis. The chi-square test 
was applied to the count data for statistical analysis. P<0.05 was 
considered significant.
3.  Results
3.1. Levels of miR-155 in PBMCs and miR-155
  Figure 1 shows the same trend of miR-155 expression levels 
between plasma and PBMCs, in the four kind of blood sample. The 
miR-155 levels declined as the disease become more severe: the 
highest miR-155 level came from the CPS group, followed by the 
SAP and UAP groups, and the AMI group had the lowest expression 
level. In PBMCs, the miR-155 levels were much higher than the 
other three groups, and the difference was statistically significant 
(P<0.05). In plasma, there were no significant differences between 
the miR-155 levels of the CPS and SAP groups (P>0.05), however, 
the miR-155 levels of the CPS group were obviously higher than the 
UAP and AMI groups (P<0.05). 
  In PBMCs, the miR-155 level in the CPS group was higher than 
in the SAP, UAP, and AMI groups; the differences were statistically 
significant (CPS vs. SAP t=28.891, P=0.000; CPS vs. UAP t=20.739, 
P=0.000; CPS vs. AMI t=26.118, P=0.000). In plasma, the miR-
155 level in CPS was higher than in the UAP and AMI groups; the 
differences were statistically significant (CPS vs. SAP t=10.065, 
P=0.167; CPS vs. UAP t=10.774, P=0.005; CPS vs. AMI t=15.036, 
P=0.000).
3.2. miR-155 levels in PBMCs and plasma
  Spearman correlation coefficients were used in evaluating and 
analyzing the correlation of miR-155 expression levels in PBMCs 
and plasma; and the results revealed that miR-155 levels has a 
positive correlation with PBMCs and plasma (r=0.861, P=0.000 
(Figure 2).
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Figure 1. MiR-155 expression levels in PBMCs and plasma. 
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Figure 2. Correlation of miR-155 levels with PBMCs and plasma.
3.3. miR-155 levels between CAD blood sample and non-
CAD blood sample
  Patients were diagnosed with CAD when the degree of coronary 
stenosis was higher than 50%. As shown in figure 3, the miR-155 
level in PBMCs was higher in the non-CAD group than in the CAD 
group (2.705依0.310 and 0.983依0.220, respectively); and the miR-
155 level in plasma was also higher in the non-CAD group than in 
the CAD group (2.060依0.410 and 1.128依0.250, respectively).
  In PBMCs and plasma, the miR-155 levels in CAD patients were 
lower than non-CAD patients, and the difference was statistically 
significant (In PBMCs: non-CAD vs. CAD t=11.550, P=0.000; in 
plasma: non-CAD vs. CAD t=14.003, P=0.002).
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3.4. Expression of miR-155 was induced by OxLDL by 
RAW264.7 macrophage 
  The level of miR-155 was detected by Real-Time PCR. We found 
that, after treated with OxLDL, the expression level of miR-155 in 
RAW264.7 macrophage raised with the improvement of the OxLDL 
concentration (Figure 3).
3.5. OxLDL reduce the viability of RAW264.7 macrophage
  After treated with OxLDL of different concentration for 24 h, the 
viability of RAW264.7 macrophage declined with the concentration 
improved. Compared with the control group, the viability of the 
cell treated with the concentration of 20, 40, 80 and 160 毺g/mL 
declined obviously, and the difference was statistically significant 
(P<0.05). When treated with OxLDL at the concentration of 80 毺
g/mL, the viability of the cell also declined with the time prolonged. 
Compared with the control group, the viability of the cell at 24 and 
48 hours improved significantly (P<0.05) (Figure 4).
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Figure 3. OxLDL induce the expression of miR-155 in RAW264.7 
macrophage. 
A: as the concentration of OxLDL incr RAW264.7 macrophage eased, the 
expression level of miR-155 in RAW264.7 macrophage improved; compared 
with the control group, *P<0.05. B: treated RAW264.7 macrophage with 
OxLDL with the concentration of 80 毺g/mL, the expression level of miR-
155 improved as the treatment time prolonged; compared with the control 
group, *P<0.05.
3.6. Effort of OxLDL on the miR-155 overexpressed 
RAW264.7 macrophage
  After treated with OxLDL, the viability of the cell in the 
control group, miR-155 overexpression group, and the miR-
155 overexpression + miR-155 inhibitor group declined with the 
treatment time prolonged. And the viability of the cell in miR-
155 overexpression group was much higher than the control group 
and the inhibitor group in the 12, 24 and 48 h, the difference is 
statistically significant (P<0.05). There was no statistical difference 
between the control group and the inhibitor group (P>0.05) (Figure 
5).
 
120
100
80
60
40
20
0
C
el
l v
ia
bi
lit
y
120
100
80
60
40
20
0
C
el
l v
ia
bi
lit
y
0                10                20                40               80           160 (毺g/mL)
0 h               3 h              6 h              12 h            24 h             48 h
* *
*
*
 
Figure 4. OxLDL reduce the viability of RAW264.7 macrophage. 
A: with the concentration of OxLDL improved, the viability of RAW264.7 
macrophage declined gradually; compared with the control group, *P<0.05. 
B: after treated with OxLDL with the final concentration of 80毺g/ml, the 
viability of the RAW264.7 macrophage declined with the treatment time 
prolonged; compared with the control group, *P<0.05.
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Figure 5. Viability of miR-155 overexpression RAW264.7 macrophage after 
treated with OxLDL.
After treated with OxLDL, the viability of the cell in the three group were 
all declined with the treatment time prolonged. Compared with the control 
group, the viability of the cell in the inhibitor group declined obviously at 12, 
24, 48 h, while there was no statistical significance between the control group 
and the miR-155 overexpression group. Compared with the control group, 
*P<0.05.
4. Discussion
  miR-155 is a key factor that regulates inflammatory reactions and 
participates in inflammatory related diseases, while CAD is a kind of 
inflammatory disease; To elucidate the relationship of miR-155 with 
CAD, we measured the PBMCs and plasma miR-155 levels of blood 
sample form patients with CPS, SAP, UAP, and AMI; and analyzed 
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the relationship of miR-155 with the severity of CAD and plaque 
stability; detected the effort of OxLDL on RAW264.7 macrophage 
and miR-155 overexpression RAW264.7 macrophage, analyzed 
the effort of miR-155 on the apoptosis of RAW264.7 macrophage, 
these results further confirmed that miR-155 levels declines as 
CAD progresses and the overexpression of miR-155 can inhibit the 
apoptosis of . RAW264.7 macrophage induced by OxLDL.
  The miR-155 gene is located in chromosome 21q21, a highly 
conserved coding region within the third extron of the B-cell 
integration cluster gene[9,10]. Research revealed that miR-155 
has been found up-regulated in several activated immune cells; 
which could modulate the immune response by regulating the 
differentiation of the immune cells, such as Th1 cell and T cell, 
and the secretion of cytokines[11,12]. Apart from inflammatory 
stimulation, the Oxidized LDL, which plays an important role in 
atherosclerosis, can also stimulate the THP-1 macrophage, and up-
regulate the miR-155 level, which suggests that miR-155 plays an 
important role in CAD[13,14]. Fichtlscherer et al[15] found that miR-
155 levels declines, as CAD progresses; while Menno Hoekstra et 
al[16] reported that there was no significant difference between the 
patient’s miR-155 levels and the different degrees of CAD.
  Our results showed that the miR-155 levels in plasma and PBMCs 
gradually declined from SAP to AMI blood sample. According to the 
correlation analysis, miR-155 levels in plasma were positively related 
to the levels in PBMCs. Although, the process on how miR-155 is 
released in blood circulation is still unclear, it can still be detected in 
serum, at a steady form[17]. This phenomenon revealed that miR-155 
can resist RNA enzyme dependent degradation. During cell culture, 
miR-155 secretion can be stimulated by serum elimination[18,19]. 
Moreover, miR-155 can also be detected in endothelial cell-derived 
apoptotic bodies; and the RNA, incorporated into apoptotic bodies 
or microvesicles, can be delivered into recipient cells[20]. Combined 
with the results of our study, wherein, miR-155 can be detected in 
peripheral blood and that miR-155 levels in plasma has the same 
trend as the levels in PBMCs, we can deduce that miR-155 in plasma 
may have originated from PBMCs.
  There was an over expression of miR-155 in the plaque and 
macrophage of patients with atherosclerosis[21,22], which suggesting 
that miR-155 could participate in the development of atherosclerosis. 
Although, miR-155 could accelerate inflammatory reactions and 
cell apoptosis at the same time[23], its function in atherosclerosis is 
still controversial. In our study, we found that the miR-155 levels in 
blood sample from patients with CAD were lower than blood sample 
from patients without CAD. This suggests that the miR-155 levels 
were negatively related to the severity of coronary lesions. Combined 
with the research of Li et al[24,25], we can speculate that miR-155 
has a vascular protective effect; miR-155 can control inflammation 
and reduce tissue damage through its negative feedback effects on 
inflammatory factors. Moreover, miR-155 can also directly act on 
angiotensin 栻-1 receptors, preventing it to bond with angiotensin 
栻; which may block endothelial cell migration, repress angiotensin 
栻-1 transcription, and inhibit the occurrence and development of 
atherosclerosis[26,27].
  The improvement of apoptosis in vivo is a major cause of CAD, but 
the action mechanism is still unclear. The opoptosis of macrophage 
has been confirmed to be an outstanding factor in advanced 
atherosclerotic plaque. In this study, we use miR-155 mimics as 
intervention factor, induce the apoptosis of macrophage by OxLDL 
to stimulate the apoptosis process of macrophage in vivo. We found 
that OxLDL can induce the apoptosis of macrophage in an time 
and dosage dependent way. We also found, OxLDL can induce 
the expression of miR-155 improved slightly. The overexpression 
of miR-155 can improve the viability of macrophage, inhibit the 
apoptosis induced by OxLDL and the phenomena can be inhibited 
by miR-155 inhibitor. These results suggest that the regulation effort 
of OxLDL and miR-155 on the apoptosis of macrophage is achieved 
by a negative feedback pathway. Zhu et al[28] reported, miR-155 
suppress the apoptosis of macrophage by regulate FADD.
  In conclusion, the miR-155 levels of CAD patients were higher 
than non-CAD patients, and the miR-155 levels declined as the 
disease developed. The over expression of miR-155 can inhibit 
the apoptosis of macrophage induced by OxLDL. Therefore, the 
miR-155 in circulation may potentially serve as a new marker for 
cardiovascular disease. However, our study still has its deficiencies. 
For inflammatory related small miRNAs, it is still unclear whether 
other inflammatory diseases would affect the expression level of 
miR-155, and further affect the sensitivity and specificity of CAD 
diagnosis. Further study should be done to confirm the possibility of 
clinically displacing the tradition marker.
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